Clinical trials

The following list shows the clinical trials currently open at the two sarcoma centres in London and the South East: University College London (UCLH) and The Royal Marsden (RMH). For further information please contact the research nurses at each site:

Last updated December 2023

Name Description Type Centre Age
BI 1403-0002 Phase Ib part will be performed in patients with TP53 wt advanced and/or metastatic, soft tissue sarcomas Phase Ib RMH
C-800 Phase I study of AGEN1181 alone or with AGEN2034 in advanced cancer Phase I RMH
COGENT PEAK Phase III Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors Phase III RMH,
>18 years
EHE Biobank UK Biobank for epithelioid haemangioendothelioma RMH
EHE Study Milan Evaluation of cytokines and hormonal profile as biomarker in epithelioid haemangioendothelioma RMH
EMPRASS Elucidation of a molecular signature of pazopanib response in advanced soft tissue sarcoma including solitary fibrous tumours (EMPRASS study) RMH
ENVASARC A pivotal trial of envafolimab, and envafolimab in combination with ipilimumab, in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy. Phase II RMH ≥ 12 years
EORTC QOL Incorporating the patient voice in sarcoma research: How can we assess health-related quality of life in this heterogeneous group of patients UCLH >18 years
FaR RMS An overarching study for children and adults with frontline and relapsed rhabdomyosarcoma UCLH >12 months, ≤40 years
GIST Biobank Biobank for GIST RMH
GSK 7011618 SCOOP Phase I Niraparib and Dostarlimab in paediatric patients with recurrent or refractory solid tumours Phase I ULCH <18 years
ICONIC Improving outcomes through collaboration in osteosarcoma UCLH
ImmunoSARC Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas Phase I-II UCLH >12 years
INBRX-109 (ChonDRAgon) A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma Phase II RMH,
>18 and <85 years
KINDRED The International Sarcoma Kindred Study: a global multi‐site prospective cancer genetics study. Translational RMH
≥15 years
OligoRARE (EORTC 1945) Stereotactic body radiotherapy in addition to standard of care treatment in patients with rare oligometastatic cancers (OligoRARE): a randomized, phase 3, open-label trial RMH
PANTHR-S Precision medicine approaches for neoadjuvant therapy in high‐risk sarcoma patients (PANTHR-S) RMH
PREDICT B Predicting radiotherapy response, toxicities and quality of life related functional outcome in soft tissue sarcoma of the extremities: a prospective observational cohort study RMH,
≥16 years
PROSPECTUS PROgnoStic and PrEdiCTive ImmUnoprofiling of Sarcomas (PROSPECTUS) Retrospective TR study RMH
PTC596-ONC-008-LMS A Phase II/III Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma Phase II/III RMH,
≥18 years
Radiomics in Liposarcoma Radiomics In Liposarcoma RMH
rEECur International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory ewing sarcoma. Phase II/III RMH
>4 years and < 50 years
RINGSIDE A Phase II/III, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors Phase II/III RMH,
≥12 years
RT Immune A European, Multicentre, Randomized, Open-label, Phase II Trial, aiming to assess the clinical and biological activity of an anti-PD-L1 (atezolizumab) in operable localised soft tissue sarcomas patients to be treated with radiotherapy. Phase II RMH
SMPaeds Stratified medicine paediatrics: genomic characterisation of relapsed paediatric cancers for diagnostics and stratified therapy UCLH Paediatric tumours only
SPEARHEAD 1 A phase II single arm open-label clinical trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Phase II UCLH ≥16 and <75 years